NASH Pipeline: Racing To The Finish
Executive Summary
As industry closes in on the first approved drug therapy for non-alcoholic steatohepatitis, our infographic details the dozens of companies testing numerous mechanisms for the multi-factorial disease.
You may also be interested in...
Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
Inventiva Moves Up In NASH, Hitting Multiple Phase IIb Endpoints
A month after Genfit’s Phase III failure, Inventiva hits multiple endpoints in a Phase IIb study of pan-PPAR agonist lanifibranor – likely drawing partnering or acquisition interest. Ascletis offers Phase II evidence for its NASH drug.
Axcella Addresses Metabolic Disease Quickly With GRAS Candidates
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.